key: cord-0688169-3w3wjzhi
authors: Garrido, Carolina; Curtis, Alan D.; Dennis, Maria; Pathak, Sachi H.; Gao, Hongmei; Montefiori, David; Tomai, Mark; Fox, Christopher B.; Kozlowski, Pamela A.; Scobey, Trevor; Munt, Jennifer E.; Mallroy, Michael L.; Saha, Pooja T.; Hudgens, Michael G.; Lindesmith, Lisa C.; Baric, Ralph S.; Abiona, Olubukola M.; Graham, Barney; Corbett, Kizzmekia S.; Edwards, Darin; Carfi, Andrea; Fouda, Genevieve; Van Rompay, Koen K. A.; De Paris, Kristina; Permar, Sallie R.
title: SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques
date: 2021-04-06
journal: bioRxiv
DOI: 10.1101/2021.04.05.438479
sha: cb9eb2a16911431bbcf1fb851c9796dc2da049f3
doc_id: 688169
cord_uid: 3w3wjzhi

Early life SARS-CoV-2 vaccination has the potential to provide lifelong protection and achieve herd immunity. To evaluate SARS-CoV-2 infant vaccination, we immunized two groups of 8 infant rhesus macaques (RMs) at weeks 0 and 4 with stabilized prefusion SARS-CoV-2 S-2P spike (S) protein, either encoded by mRNA encapsulated in lipid nanoparticles (mRNA-LNP) or mixed with 3M-052-SE, a TLR7/8 agonist in a squalene emulsion (Protein+3M-052-SE). Neither vaccine induced adverse effects. High magnitude S-binding IgG and neutralizing infectious dose 50 (ID50) >103 were elicited by both vaccines. S-specific T cell responses were dominated by IL-17, IFN-γ, or TNF-α. Antibody and cellular responses were stable through week 22. The S-2P mRNA-LNP and Protein-3M-052-SE vaccines are promising pediatric SARS-CoV-2 vaccine candidates to achieve durable protective immunity. One-Sentence Summary SARS-CoV-2 vaccines are well-tolerated and highly immunogenic in infant rhesus macaques

We evaluated the capacity of plasma antibodies to block entry of SARS-CoV-2 into human cells using a 100 RBD-ACE2 blocking assay at 1:10 and 1:40 plasma dilutions. Antibodies elicited by the mRNA-LNP vaccine completely blocked RBD-ACE2 interaction at week 6 at 1:10 and 1:40 dilutions. Until W14, >80% blocking was achieved at 1:10 dilution, dropping for some animals after W18 (Fig. 3A) . The Protein+3M-052-SE vaccine induced antibodies that mediated 100% RBD-ACE2 blocking after the second immunization, even at 1:40 plasma dilution, and this response was maintained throughout the study in 5 of 8 animals (Fig. 3A, Fig. S4 ). 105

Soluble ACE2 protein, as measured by ELISA, was absent from infant plasma through week 22 (data not shown). respectively. However, at week 22, median ID80 titers remained higher (2.6-fold or 14.2-fold in the mRNA-LNP or Protein+3M-052-SE group, respectively) than after the first vaccination (week 4) (Fig. 3B) . A bi-phasic antibody decline was modeled for both vaccines, estimating that mRNA-LNP vaccinees maintain a protective 115 neutralizing Ab titer, estimated at a reciprocal dilution of 100, for approximately 46 weeks. Protein vaccine recipients sustain protective levels for approximately 74 weeks (Fig. S5) . Importantly, ID50 neutralization titers in the mRNA-LNP group at week 8 were comparable to those observed in adult RMs after immunization with the same S-2P mRNA-LNP vaccine (16) (Fig. S6 ). In the whole virus neutralization assay, low titer neutralizing antibodies were detected at day 0 that increased post vaccination following a similar trend (Fig.3C) , and ID80 120 titers correlated with those obtained in the pseudovirus neutralization assay (r = 0.785, p=0.0005, Fig. S6 ).

Whole virion neutralization was also measured in dam sera, observing some low-level neutralization titers that did not correlate to infant neutralization before (ID80: r=0.011, p=0.9681) or after vaccination (ID80: r=-0.056, p=0.8362) (Fig. S7 ).

frequencies were lower (0.19% and 0.13% in mRNA-LNP or Protein+3M-052-SE vaccinees, respectively), but did not differ from those at week 4 (Fig. 4A) . Robust memory B cell populations (median 3.78% mRNA-LNP and 1.96% Protein-3M-052) were present in lymph nodes (LNs) (Fig. 4B) . Induction of S-specific B cells was 130 confirmed by assessing S-specific antibody secreting cells (ASC). In blood, peak responses were observed at week 6 in the mRNA-LNP group (median: 154 ASC/million cells) and at week 8 in Protein+3M-052-SE vaccinees (median: 85 ASC/10 6 cells); S-specific ASC remained detectable at all time points in both groups ( Fig. 4C) . In draining LNs, mRNA-LNP and Protein+3M-052-SE vaccinees had median 6 or 952 ASC/10 6 cells, respectively (Fig. 4D ). Combined data from both vaccine groups showed neutralizing ID50 titers at weeks 6 and 135 8 correlated with ASC (r=0.547, p=0.03 and r=0.632, p=0.01, respectively) ( Fig. S9A-B ), but not with LN Sspecific memory B cells. Total LN Ki-67 + Bcl6 + germinal center (GC) and CD27 + memory B cells (Fig. 5A ) were also not correlated with neutralizing antibody titers.

LN CD4 + T cells were analyzed for IL-4 and IL-21, cytokines supporting GC B cell differentiation, and canonical T follicular helper (Tfh) (CD185/CXCR5 + CD279/PD-1 + ) cells (Fig. 5B ). CD4 + IL21 + cells correlated 140 with pseudovirus neutralizing antibody ID50 at week 6 (r=0.749, p=0.001) (Fig. S9C ). SEB-activated Tfh (CD185 + CD279 + CD134 + CD137 + ) (23) (Fig. 5C ) were categorized into Tfh1, Tfh2 and Tfh17 subsets based on expression of CXCR3/CD183 and/or CCR6/CD196 (Fig. 5D ). We found no correlations between frequencies of Tfh subsets with neutralizing antibody titers, GC or memory B cells, potentially because we measured antigennonspecific Tfh. 145

S-specific CD4 + T cell responses in PBMC could already be detected by week 4 in a subset of animals, with all animals producing at least a single cytokine by week 6 (Fig. 6) . At week 14, animals vaccinated with mRNA-LNP exhibited IL-2, IFN-g, IL-17, and TNF-a CD4 + T cell responses (Fig. 6D ). IL-17 and IFN-g CD4 + T cell responses dominated in Protein+3M-052-SE vaccinees (Fig. 6D ). Multifunctional CD4 + T cells co-produced IL-17 and IFN-g (Fig. S11 ). S-specific CD8 + T cell responses were less robust than CD4 + T cell responses and 150 only elicited in a subset of animals (Fig. S12) . LN S-specific CD4 + and CD8 + T cells were single-cytokine positive and detected in all mRNA-LNP recipients at week 6 and in 7 of 8 Protein+3M-052-SE vaccinees (Fig.   S13 ). There was no evidence of systemic IL-2, IFN-γ, IL-4, or IL-13 or in plasma samples collected prior to or following immunization in 14 of 16 animals (Fig. S14 ). Cytokines were detected in the mRNA-LNP recipient RM11 (Table S1 ) at week 0, but were below the limit of quantification by week 6. In the protein group, animal RM3 (Table S1 ) tested positive for all cytokines at both time points. Overall, the data argue against a vaccineinduced Th2 bias.

Several SARS-CoV-2 vaccines have demonstrated safety, immunogenicity and protection in clinical trials 160

(1, 5, 6) and adult animal studies (8, 16, 24, 25) . However, to date there are no data regarding the performance of these vaccines in pediatric populations. We evaluated two vaccines based on the stabilized prefusion S-2P SARS-CoV-2 protein in infant RMs: a LNP-encapsulated mRNA vaccine and an adjuvanted subunit protein.

Our results demonstrate that infant RMs develop strong, durable humoral and cellular responses in the absence of adverse events following vaccination with either vaccine candidate. 165

We assessed infant vaccine-induced immune responses over 22 weeks, analogous to adult clinical trials (1, 2). The S-2P mRNA-LNP vaccine, a preclinical version of the highly efficacious mRNA-1273 vaccine by Moderna, that is approved for emergency use in adult humans, elicited high magnitude and durable antibody and cellular responses in infant RMs. Efficacy of the first protein-based SARS-CoV-2 vaccine, Novavax NVX-CoV2373, mixed with saponin-based Matrix-M™ adjuvant, has recently been reported (8) . We tested the S-2P 170 SARS-CoV-2 protein mixed with 3M-052-SE, a TLR7/8 agonist in squalene emulsion, because this adjuvant has proven effective in eliciting high magnitude antibody responses to other vaccines in infant RMs (26, 27) .

Indeed, the 3M-052-SE formulated S-2P protein induced robust and persistent IgG binding and neutralization responses.

Both vaccines elicited plasma antibodies dominated by IgG and recognized all Spike protein domains. 175

Interestingly, RBD-specific IgG was also detected in saliva, especially in animals of the protein vaccine group, and remained detectable throughout the study, similar to what has been observed after human natural infection (28). Moreover, 7 of 8 Protein-3M-052-SE vaccinated animals had RBD-specific IgA after the 2 nd immunization.

Salivary RBD-specific IgG and IgA may either be mucosally produced or transudated from plasma.

Binding and neutralizing antibodies persisted throughout the study in all animals of both groups, 180 comparable to results in clinical trials with human adults. In adult NHP, a vaccine-induced pseudovirus neutralizing antibody ID50 titer of 50 is thought to protect against susceptible SARS-CoV-2 strains (29). As median ID50 titers exceeded 10 3 for the protein vaccine group and 10 2 for the mRNA group at week 22, we hypothesize that pediatric vaccination would provide long-term protection against SARS-CoV-2 infection, with the potential need to include additional S variant antigens of newly emerging SARS-CoV-2 variants into 185 vaccine candidates as necessary.

Early life immunity is associated with Th2-biased T cell responses (30), and Th2 responses have been linked to vaccine-associated enhanced respiratory disease in the context of protein or inactivated virus vaccines (6, 31, 32) . We observed a Th1/ Th17-skewed cytokine profile in circulating S-specific T cells. Our finding of peak S-specific T cell responses 10 weeks post-boost are not unexpected. A recent study of T cell 190 reactivity in convalescent COVID-19 patients highlighted T cell responses with augmented frequency and potency 100 days post-recovery even as S-specific antibody waned (33). Indeed, ~93% of "exposed asymptomatic" patients possess SARS-CoV-2-specific memory T cell subsets in the absence of seroconversion (34). Higher Tfh2 frequencies compared to Tfh1 does not necessarily imply a Th2-bias as Tfh17 cells were also detected, and Tfh were not assessed for antigen specificity. More importantly, IL-4 and 

Figs. S1 to S15 Tables S1 to S3

References (39-53) Antibody epitope specificity measured by BAMA. Plasma was diluted 1:10,000 to measure binding to different domains of the spike protein, including the full-length S protein, S1, RBD, NTD, and S2. Binding antibody responses are reported as log10 transformed mean fluorescence intensity (MFI) after subtraction of background values. Red or blue lines and symbols represent the mRNA or protein vaccine groups, respectively, with 385 different symbols representing individual animals (Table S1 ). (Table S1 ). (Table S1 ). Solid lines represent median values. (Table S1 ). Solid lines define the median. 410 (Table S1) . 

IgG binding to S-2P (2019-nCoV) and the D614G variant was measured in plasma using enzyme-linked immunosorbent assay (ELISA), following published protocols (40) . IgM and IgA binding to S-2P was measured in 1:10 diluted plasma by ELISA. To assess epitope-specificity, IgG binding to the RBD, NTD, S1, S2 and the whole spike, was measured by a Luminex-based binding antibody multiplex assay (BAMA) at a dilution of 505 1:10,000 (40) . RBD-specific IgG and IgA in saliva were quantified in serially diluted samples using BAMA, and results normalized to total IgG and IgA (see Supplementary Material for more details). Pseudovirions were produced in HEK 293T/17 cells by transfection using a combination three plasmids:

full-length Spike with D614G mutation, lentiviral backbone (pCMV ΔR8.2) and firefly Luc reporter gene (pHR' CMV Luc) (41). Luminescence was measured using a PerkinElmer Life Sciences, Model Victor2 luminometer 515 after addition of Bright-Glo luciferase reagent. Neutralization activity is expressed as the reciprocal dilution at which the relative light units (RLU) were reduced by 50% (ID50) or 80% (ID80) relative to virus-only control wells. Whole virus neutralization was performed with a SARS-CoV-2 nanoLUC carrying the D614G mutation as described (42) .

Soluble ACE2 and cytokine measurement 520 (Table S3) . Total CD20 + and/or memory CD27 + S-specific B cells were identified as double-positive for biotinylated S-2P protein labeled with avidin-APC or avidin-PE (Fig. S8 ). Germinal center (GC) B cells were analyzed by flow cytometry (Table S2 ) as detailed elsewhere (43) . Samples were acquired using an LSRFortessa (BD) and analyzed with 530 (Table S3 ) as described (43) . Activation-induced marker (AIM) T follicular helper cell (Tfh) responses were quantified in LN-MNC stimulated with 5 µg/mL Staphylococcal enterotoxin B (Toxin Technologies) or vehicle DMSO for 18h (23) and analyzed by flow cytometry (Table S3 , Fig. S15) . 540

Spearman's rank correlations were estimated between pre-specified parameters at specific timepoints.

Statistical analyses were performed using SAS version 9.4 (Cary, NC, USA). ID50 neutralization titer decline half-life was estimated based on random-effects regression models of decay with first-order kinetics (44, 45) . The cell + transfection mixture was then split between two 2-liter Corning flasks for a final volume of 560 approximately 500mL each and placed on a platform shaker in a humidified incubator at 37°C with 8% CO2.

The shaker speed was set to 120rpm and the flasks allowed to incubate for 6 days. At the end of the 6-day incubation, the flasks containing the transfected cells were removed from the incubator and the contents of the flasks were aseptically transferred to 500mL Corning centrifuge tubes. The supernatant was clarified by centrifugation and subsequently filtered using a 0.8µm filter bottle system. Keeping the clarified and filtered supernatant on ice, the supernatant was concentrated using a Sartorius Vivaflow 200 30kDa TFF system. In preparation for the purification of the CoV2 Spike protein, 4mL of Strep-Tactin Resin (iba Life Science) was placed in a conical tube. The concentrated supernatant was transferred to the conical tube containing the Strep-Tactin resin and allowed to bind with gentle agitation. The supernatant and resin were then transferred to a polypropylene column for gravity-flow chromatography (BioRad). Once the resin had settled in the column 570 the resin was washed and the protein eluted following instructions supplied by the vendor (iba Life Science).

The eluate was buffer-exchanged into 2mM Tris and 200mM Sodium Chloride storage buffer using Millipore Centrifugal filters. The resulting material was finally filtered through a 0.2um syringe filter (Pall) and stored in storage buffer. Additional purification by size exclusion chromatography over a Superose 6 column was performed to increase purity. 575

Saliva was collected with absorbent Merocel sponges (Beaver Visitec) by placing a sponge between the cheek and gum in the back of the mouth for 5 minutes. Secretions were eluted by centrifugation at 18,000 g and 4˚C after addition of 50µl of PBS containing protease inhibitors (48), 1% TritonX-100, 1% BSA, 0.05% azide, and 0.05% Tween-20 to sponges. A customized binding antigen multiplex assay (BAMA) was used to 580 measure IgG or IgA antibodies to SARS CoV-2 recombinant receptor binding domain protein (RBD; generously provided by Dr. Wrammert, Emory University, Atlanta, GA) and S2 extracellular domain (SinoBiologicals #40590-V08B, Wayne, PA). Briefly, proteins were dialyzed in PBS and conjugated to Bioplex Pro carboxylated magnetic beads (Bio-Rad, Hercules, CA) using N-hydroxysulfosuccinimide and ethylcarbodiimide as described (49) . Serial dilutions of standard and centrifuged salivary secretions in PBS containing 1% TritonX-100, 1% 585 BSA, 0.05% azide, and 0.05% Tween-20 were mixed with RBD+S2 beads overnight at 1100rpm and 4˚C using a plate mixer. The IgG standard was a cocktail of anti-S1 RBD (Genscript #HC2001) and anti-S2 (SinoBiologicals #40590-D001) humanized IgG monoclonal antibodies. The standard for IgA assays was a pooled serum from infected rhesus macaques (50) that had been calibrated relative to the previously mentioned monoclonal antibodies. The following day, beads were alternately washed using a Bio-Rad BioPlex 590 wash station and treated for 30min with 2µg/ml biotinylated affinity-purified goat antibody to human γ chain (SouthernBiotech Associates, Birmingham, AL) or clone IgA5-3B mouse anti-monkey IgA (Bio-Rad) followed by 1/400 avidin-phycoerythrin (Southern Biotechnology Associates). A Bio-Rad Bioplex 200 and BioManager software were used to measure fluorescent intensity and construct standard curves for interpolation of antibody concentrations in test samples. Concentrations of antibody measured in BAMA were normalized relative to the 595 total IgG and IgA measured by ELISA as described (48) using plates coated with goat anti-monkey IgG or IgA and the secondary antibodies above.

Mapping plasma S-specific IgG SARS-CoV-2 antigens, including whole spike (produced by PPF), S1 (Sinobiological cat# 40591-V08H), S2 firefly Luc reporter gene plasmid (pHR' CMV Luc) (51) in a 1:17:17 ratio. Transfections were allowed to proceed for 16-20 hours at 37oC. Medium was removed, monolayers rinsed with growth medium, and 15 ml of fresh growth medium added. Pseudovirus-containing culture medium was collected after an additional 2 days of incubation and was clarified of cells by low-speed centrifugation and 0.45 µm micron filtration and stored in 625 aliquots at -80oC. TCID50 assays were performed on thawed aliquots to determine the infectious dose for neutralization assays. Neutralization titers are the serum dilution at which relative luminescence units (RLU) were reduced by either 50% (ID50) or 80% (ID80) compared to virus control wells after subtraction of background RLUs. Serum samples were heat-inactivated for 30 minutes at 56C prior to assay.

Neutralization of SARS-CoV-2 nanoLUC carrying the D614G mutation was assessed as described in Hou et al with modifications (52) . Briefly, under BSL-3 containment, serially diluted sera at 8 dilutions were incubated for one hour with SARS-CoV-2 D614G nanoLUC virus at 5% CO2 and 37˚C. After incubation, the virus/antibody mixtures were added in duplicate to black 96-well plates containing Vero E6 cells (2 x 104 cells/well). Each plate contains virus-only (no serum) control wells. The plates were incubated for 24 hr at 37 645 ˚C, 5% CO2, the cells lysed, and luciferase activity measured with the Nano-Glo Luciferase Assay System (Promega). Neutralization activity is expressed as the dilution concentration at which the observed relative light units (RLU) are reduced by 50% or 80% relative to virus-only control wells.

Corning 384-well plates were coated with 3.5 ug/mL ACE2 protein (Sinobiological) 24 hours before 650 conducting the experiment. The day of the assay, the plate was blocked with assay diluent (phosphatebuffered saline containing 4% whey, 15% normal goat serum, and 0.5% Tween 20) for 1 hour at room temperature. Plasma was diluted 1:10, 1:40, or 1:60 using the assay diluent, and incubated with 1 ug/mL HRP-RBD protein (Genescript) at 37C for 1 hour. Plates were washed and the preincubated mixture of plasma and HRP-RBD protein was added in duplicates and incubated at RT for 1 hour. Then, plates were washed 4 times 655 to remove unbound sample, and peroxidase substrate solution (SeraCare) was added for 4 minutes before stopping the reaction using stop solution (SeraCare). Signal was detected using a Spectramax plate reader at OD 450. The amount of signal detected in wells without sample (diluent only) was considered the maximal binding response, and the OD450 detected in the sample wells was transformed to percentage inhibition compared to maximum binding. Data presented is the average of two replicates when CV is less than 20%, 660 and if different assays were performed, median value was considered.

To express the prefusion S ectodomain, a gene encoding residues 1−1208 of 2019-nCoV S (GenBank: MN908947) with proline substitutions at residues 986 and 987, a "GSAS" substitution at the furin cleavage site T cell cytokine assay Frozen cells were thawed, or fresh preparations were washed and cultured in cRPMI (106/mL) with or without 2 µg/mL overlapping peptides spanning the length of SARS-CoV-2 spike protein (JPT Technologies) or 710 DMSO vehicle together with antibodies against co-stimulatory CD28 and CD49d from BD. Naïve donor cells were included with each assay and, in addition to peptide pool or vehicle, were stimulated with 0.5x cell stimulation cocktail (eBiosciences) as a positive control. Cells were surface stained as outlined in Table S2 and then permeabilized with BD CytoFix/CytoPerm per manufacturer's recommendations and stained with intracellular antibodies as prescribed in Table S2 . Data were collected using an LSRFortessa and BD 715 FACSDiva v8.0 and analyzed with FlowJo software v10.7.1 (TreeStar). Intracellular cytokine gates were Boolean gated and reported as single positive events unless otherwise noted.

The activation-induced marker (AIM) assay was performed on cryopreserved LNC. Cells were thawed, rested 3 h at 37°C with 5% CO2, resuspended in AIM V medium (Gibco), and transferred at 106 cells per well 720 to a 24-well plate. Cells were cultured with vehicle DMSO (negative control) or with 0.5 μg/ml staphylococcal enterotoxin B (Toxin Technologies) for 20 hours at 37°C with 5% CO2. After stimulation, cells were stained with prescribed antibodies per Table S2 and acquired immediately on an LSRFortessa instrument running FACSDiva v8.0 software (BD Biosciences) and analyzed as described above. (Table S1) . (Table S1 ). Whole virion neutralization (WVNA) was measured in dams and in infants before the vaccine (W0) and after 780 the vaccine boost (W6). There was no correlation of ID50 or ID80 neutralization titers between infants and dams (Spearman rank analysis). Blue symbols correspond to protein vaccine and red symbols to mRNA-LNP. Panel A shows a representative plot from RM7; Panel B shows a naive, age-matched control macaque without SARS-CoV-2 S protein conjugates; Panel C shows the same donor macaque with the SARS-CoV-2 S protein conjugates included.

Panels A and B show the correlation between neutralizing antibody ID50 titers with lymph node ASC numbers at W6 and W8, respectively. Panel C defines the association between lymph node CD4 + IL-21 + T cells at W6 and neutralization titers. Each symbol represents a single animal, animals from both vaccine groups were 795 included in the analysis. Correlations were assessed by Spearman rank test. (Table S1) . 805 S1). Dotted lines represent the cut-off for cytokine-positive responses, determined as 2 standard deviations above median values of SARS-CoV-2 naïve animals. 815

Intracellular cytokine staining as in Figure 5 in lymph node biopsy samples at week 6 to measure Spike-820 specific T cell responses. Panels A and B show mRNA-LNP and Protein+3M-052+SE CD4 + T-cell responses, respectively. Panels C and D represent CD8 + T cell cytokine responses from mRNA-LNP and Protein+3M-052+SE animals, respectively. Symbols and the legend mirror those from Figure 6 (see also Table S1 ). Dotted lines represent 2 standard deviations from SARS-CoV-2 naïve LN samples. Protein+3M-052-SE (blue) vaccine groups, respectively (Table S1 ). Horizontal lines represent median values. 

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study

Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children

One Year Later, How Does COVID-19 Affect Children?

Challenges in infant immunity: implications for responses to infection and vaccines

Glycoconjugate vaccines: Principles and mechanisms

Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-235 borns than in adults

Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. bioRxiv

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv : the preprint server for biology

Evaluation of the immunogenicity of prime-boost vaccination with the replication-245 deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

The rhesus macaque pediatric SIV infection model -a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategies

Evolution of ocular defects in infant macaques following in utero Zika virus infection

An overview of nonhuman primates in aging research

Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells

Immunogenic BNT162b vaccines protect rhesus macaques from SARS-CoV-2

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal 260 conjugate vaccine at birth

SARS-CoV-2 Vaccines Elicit Durable Immune Response in Infant Rhesus Macaques Carolina Garrido 1

A simultaneous oral and intramuscular prime/sublingual boost with a DNA/Modified Vaccinia Ankara viral vector-based vaccine induces simian immunodeficiency virus-860 specific systemic and mucosal immune responses in juvenile rhesus macaques

Co-administration of CH31 broadly neutralizing antibody does not affect development of vaccine-induced anti-HIV-1 envelope antibody responses in infant Rhesus macaques

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

SARS-CoV-2 D614G Variant Exhibits Enhanced Replication ex vivo and Earlier Transmission in vivo. bioRxiv

Oral Coadministration of an Intramuscular DNA/Modified Vaccinia Ankara 870 Vaccine for Simian Immunodeficiency Virus Is Associated with Better Control of Infection in Orally Exposed Infant Macaques

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in 875 resting CD4+ T cells

Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody

Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques

SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques

Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin

We thank Jennifer Watanabe, Jodie Usachenko, Ramya Immareddy, the Veterinary staff and Colony Research 325Services of the California National Primate Research Center for expert assistance.We thank Elise Larson, Ines De Lima, Tony Phan, Susan Lin, and Robert Kinsey from IDRI for technical assistance in preparing and characterizing 3M-052-SE.We thank Jim Giron of ThermoFisher Scientific for expert technical assistance with T cell cytokine Luminex

We thank Dr. James Peacock in the Duke Human Vaccine Institute Research Protein Production Facility. 

 Figure S1 : Weight gain of SARS-CoV-2 immunized infant rhesus macaques.Longitudinal weight data for all female (top) and male (bottom) animals from this study with their respective 730 symbol shapes and colors (Table S1) Plasma IgG binding response was assessed by ELISA using serial dilutions of plasma collected at W6 and W14. Area under the curve (AUC) was compared between binding to D614 spike protein, the immunogen in both vaccines, and the G614 spike protein that was used in the neutralization assays because it represented the dominant variant at study initiation. Different symbols represent individual animals in the mRNA-LNP (red) or Protein+3M-052-SE (blue) vaccine groups, respectively (Table S1 ). Horizontal lines represent median 740 values.